Interactions between life expectancy and the incidence and mortality rates of cancer in China: a population-based cluster analysis

OBJECTIVE: To assess the impact of asthma on Canadian mortality rates over a 45-year period.DESIGN: A descriptive, population-based study.SETTING: Canada.SUBJECTS: All persons who died from asthma in Canada from 1946 to 1990 as reported to Statistics Canada in Ottawa.MAIN OUTCOME MEASURES: Standardized mortality ratios, age-specific patterns of death, potential years of life lost (PYLL) and life expectancy lost.RESULTS: A total of 12,010 male and 8486 female asthma deaths were recorded in Canada from 1946 to 1990. Mortality rates for both sexes declined from a high of between three to six deaths in 1951 to 1955 to approximately two deaths per 100,000 in 1986 to 1990, with the decline in rates being greater for males than females. Age-specific mortality rates were highest al all ages in 1951 to 1955, except for 15 to 24 years when deaths rates for the 1981 to 1985 period were greater. PYLL exhibit the same pattern as mortality, peaking in 1951 to 1955 and subsequently declining with each period. Loss in life expectancy due to asthma was about one month (not significant) in all time periods.CONCLUSIONS: Asthma mortality rates have declined significantly over the study period. This decline appears to be linked with the convergence of sex-specific rates and with changes in the patterning or age-specific mortality. The impact of asthma on the life expectancy of Canadians is small.

Download Full-text

1491Impact of COVID19 on years of life lost with and without disability across 18 European-countries

International Journal of Epidemiology ◽

10.1093/ije/dyab168.017 ◽

2021 ◽

Vol 50 (Supplement_1) ◽

Author(s):

Sara Ahmadi-Abhari ◽

Piotr Bandosz ◽

Mika Kivimaki ◽

Lefkos Middleton

Keyword(s):

Cardiovascular Disease ◽

Life Expectancy ◽

Mortality Rates ◽

European Countries ◽

Accurate Estimation ◽

Years Of Life Lost ◽

Incidence And Mortality ◽

The Impact ◽

Prevalence Of Dementia ◽

Incidence Of Dementia

Abstract Background To accurately assess the impact of COVID19 on life-expectancy, years of life lost, and prevalence of dementia and disability, a model integrating calendar-trends in cardiovascular-disease, dementia, disability and mortality is required. We estimated these impacts in Austria, Belgium, Czech-Republic, Denmark, Estonia, France, Germany, Greece, Hungary, Italy, The Netherlands, Poland, Portugal, Slovenia, Spain, Sweden, Switzerland, and the UK. Methods Data to inform the ten-state Monte-Carlo Markov-model for the 18 European countries were derived from official-statistics for population-numbers and mortality-rates (age&sex-specific) and from Survey for Health, Ageing and Retirement in Europe for prevalence-estimates and transition-probabilities. Impact of COVID19 was measured comparing the estimates derived from incorporating expected mortality rates assuming calendar-trends in mortality and incidence of dementia, disability, and cardiovascular-disease continue those of the past two-decades, and those incorporating excess COVID19 mortality. Results Assuming COVID-19 vaccination and termination of the pandemic will be accomplished by the end of 2021, the pandemic will have resulted in a loss of 9.3M (95% Uncertainty-Interval 1.3M-29.8M) person-years of life, including 7.1M person-years of dementia-free life and 5.2M person-years of disability-free life among the 289M population (as of 2019) above age-35. The effects on prevalence of dementia, disability and life-expectancy will be presented. Conclusions The impact of the pandemic on disability-free person-years of life lost are devastating, marking a need for more rapid actions to halt the spread of epidemics. Key messages Accurate estimation of future prevalence of dementia and disability to quantify the impact of the pandemic on years of life lost needs to simultaneously account for the declining trends in incidence of dementia and the decline in cardiovascular disease incidence and mortality resulting in increased life-expectancy and a larger pool susceptible to dementia and disability. The COVID19 pandemic is estimated to result in 9.3million person-years of life lost in 18 European countries including a loss of 7.1M person-years of dementia-free life and 5.2M person-years of disability-free life.

Download Full-text

Temporal trends in incidence and mortality rates of laryngeal cancer at the global, regional and national levels, 1990–2017

BMJ Open ◽

10.1136/bmjopen-2021-050387 ◽

2021 ◽

Vol 11 (10) ◽

pp. e050387

Author(s):

Jing-Yuan Wang ◽

Qiang-Wei Zhang ◽

Kaixue Wen ◽

Chen Wang ◽

Xiaolin Ji ◽

...

Keyword(s):

Laryngeal Cancer ◽

Disease Burden ◽

Temporal Trends ◽

Mortality Rates ◽

Population Based ◽

Mortality Data ◽

Average Percentage ◽

Incidence And Mortality ◽

Disease Study ◽

Incident Cases

ObjectivesLaryngeal cancer is the most prevalent entity of head and neck cancer. Knowing the trends of incidence and mortality of laryngeal cancer is important for the reduction in related disease burden.DesignPopulation-based observational study.Main outcomes and measuresThe incidence and mortality data of laryngeal cancer were retrieved from the Global Burden of Disease study 2017 online database. The estimated average percentage change was used to quantify the trends of laryngeal cancer incidence and mortality at the global, regional and national levels.ResultsGlobally, the numbers of incident cases and deaths due to laryngeal cancer increased 58.7% and 33.9%, respectively, from 1990 to 2017. However, the overall age-standardised incidence rate (ASIR) and age-standardised mortality rate decreased by 0.99% (95% CI 0.83% to 1.14%) and 1.62% (95% CI 1.50% to 1.74%) per year, respectively. These decreases were ubiquitous worldwide. However, unfavourable trends in the ASIR of laryngeal cancer were also observed in a total of 51 developing countries.ConclusionsThe incidence and mortality rates of laryngeal cancer have significantly decreased at the global level and in most countries over the past three decades. The regions that showed an increasing incidence trend deserve more attention.

Download Full-text

Incidence and mortality rates of keratinocyte carcinoma from 1998–2017: a population-based study of sex differences in Ontario, Canada

Canadian Medical Association Journal ◽

10.1503/cmaj.210595 ◽

2021 ◽

Vol 193 (39) ◽

pp. E1516-E1524

Author(s):

Evan Tang ◽

Kinwah Fung ◽

An-Wen Chan

Keyword(s):

Sex Differences ◽

Mortality Rates ◽

Population Based ◽

Population Based Study ◽

Incidence And Mortality

Download Full-text

A Population-Based Systematic Clinical Analysis With a Single-Center Case Series of Patients With Pulmonary Large Cell Neuroendocrine Carcinoma

Frontiers in Endocrinology ◽

10.3389/fendo.2021.759915 ◽

2021 ◽

Vol 12 ◽

Author(s):

Xu Sun ◽

Yijun Wu ◽

Jing Shen ◽

Chang Han ◽

Kai Kang ◽

...

Keyword(s):

Neuroendocrine Carcinoma ◽

Cox Regression ◽

Case Series ◽

Large Cell ◽

Mortality Rates ◽

Population Based ◽

Large Cell Neuroendocrine Carcinoma ◽

Rank Test ◽

Seer Database ◽

Incidence And Mortality

Background and ObjectivesThis study aims to conduct an updated systematic analysis of patients with pulmonary large cell neuroendocrine carcinoma (PLCNC) in recent decades, concerning incidence and mortality trends, demographics, treatments, survival and death causes.MethodsPatients who were diagnosed with PLCNC at the Peking Union Medical College Hospital (PUMCH) between 2000 to 2020 were retrospectively analyzed. The population-based Surveillance, Epidemiology, and End Results (SEER) database were also retrieved. Frequencies and average annual age-adjusted rates (AAR) of PLCNC patients were calculated and analyzed by Joint-point regression. Univariate and multivariate Cox regression were used for identifying prognostic factors. Predictive nomograms for overall survival (OS) and cancer-specific survival (CSS) were developed and then validated by calculating C-index values and drawing calibration curves. Survival curves were plotted using the Kaplan-Meier method and compared by log-rank test. Causes of death were also analyzed by time latency.ResultsA total of 56 PLCNC patients of the PUMCH cohort were included. Additionally, the PLCNC patients in the SEER database were also identified from different subsets. The AAR from 2001 to 2017 were 3.21 (95%CI: 3.12-3.30) per million. Its incidence and mortality rates in PLCNC patients increased at first but seemed to decline in recent years. Besides TNM stage and treatments, older age and male gender were independently associated with poorer survival, while marital status only affected CSS other than OS. The nomograms for OS and CSS presented great predictive ability and calibration performance. Surgery gave significantly more survival benefits to PLCNC patients, and chemotherapy might add survival benefits to stage II-IV. However, radiation therapy seemed to only improve stage III patients’ survival.ConclusionsThis study supported some previous studies in terms of incidence, survival, and treatment options. The mortality rates seemed to decline recently, after an earlier increase. Among PLCNC patients, most of the deaths occurred within the first five years, while other non-PLCNC diseases increased after that. Thus, careful management and follow-up of other comorbidities are of equal importance. Our study may partly solve the dilemma caused by PLCNC’s rarity and inspire more insights in future researches.

Download Full-text

Cancer incidence and mortality in the Bucaramanga metropolitan area, 2003-2007

Colombia Medica ◽

10.25100/cm.v43i4.1196 ◽

2012 ◽

pp. 290-297 ◽

Cited By ~ 6

Author(s):

Claudia Janeth Uribe ◽

Sonia Osma ◽

Victor Herrera

Keyword(s):

Metropolitan Area ◽

Cancer Incidence ◽

Cancer Registries ◽

Mortality Rates ◽

Population Based ◽

World Population ◽

Worldwide Population ◽

Limited Effectiveness ◽

Incidence And Mortality ◽

Incident Cases

Introduction: Cancer is an important cause of morbidity and mortality worldwide. Population-based cancer registries (PBCRs) make possible to estimate the burden of this condition. Objetive: To estimate cancer incidence and mortality rates in the Bucaramanga Metropolitan Area (BMA) during 2003-2007. Methods: Incident cases of invasive cancer diagnosed during 2003-2007 were identified from the Bucaramanga Metropolitan Area PBCR (BMA-PBCR). Population counts and mortality were obtained from the Colombian National Administrative Department of Statistics (NADS). We estimated total and cancer-specific crude incidence and mortality rates by age group and sex, as well as age-standardized (Segi’s world population) incidence (ASIR[W]) and mortality (ASMR[W]) rates. Statistical analyses were conducted using CanReg4 and Stata/IC 10.1. Results: We identified 8,225 new cases of cancer excluding non-melanoma skin cancer (54.3% among women). Of all cases, 6,943 (84.4%) were verified by microscopy and 669 (8.1%) were detected only by death certificate. ASIR(W) for all invasive cancers was 162.8 per 100,000 women and 177.6 per 100,000 men. Breast, cervix, colorectal, stomach and thyroid were the most common types of cancer in women. In men, the corresponding malignancies were prostate, stomach, colorectal, lung and lymphoma. ASMR(W) was 84.5 per 100,000 person-years in women and 106.2 per 100,000 person-years in men. Breast and stomach cancer ranked first as causes of death in those groups, respectively. Conclusion: Overall, mortality rates in our region are higher than national estimates possibly due to limited effectiveness of secondary prevention strategies. Our work emphasizes the importance of maintaining high-quality, nationwide PBCRs.

Download Full-text